Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Helen Reidler

Physician Assistant, Medical Baltimore, MD Physician Assistant

NPI 1639506553 CMS profile 10985827

1838 Greene Tree Rd Ste 460, Baltimore, MD 21208

Open in the dashboard

General payments

$9,980

367 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Helen Reidler of Baltimore, MD is reported in the CMS Open Payments database as having received $9,980 across 367 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,840 89
2024 General $1,317 64
2023 General $1,655 63
2022 General $3,190 90
2021 General $1,977 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Helen Reidler
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Helen Reidler were reported at $1,840. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Helen Reidler Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,977 $156 $41–$563 $132
2022 $3,190 $185 $55–$649 $149
2023 $1,655 $199 $58–$717 $160
2024 $1,317 $206 $62–$740 $164
2025 $1,840 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,857 28 payments
  2. Janssen Biotech, Inc. $1,372 37 payments
  3. Sumitomo Pharma America, Inc. $869 61 payments
  4. AstraZeneca Pharmaceuticals LP $674 5 payments
  5. Astellas Pharma US Inc $591 25 payments
  6. Pfizer Inc. $519 22 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $450 20 payments
  8. Tolmar, Inc. $279 11 payments
  9. Merck Sharp & Dohme Corporation $259 14 payments
  10. TOLMAR Pharmaceuticals, Inc. $259 10 payments
  11. Other $2,852 134 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,315 347 payments
  2. Travel and Lodging $1,405 8 payments
  3. Education $643 10 payments
  4. Consulting Fee $600 1 payment
  5. Gift $17 1 payment
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,688 27 payments
  2. ERLEADA $1,472 40 payments
  3. LYNPARZA $654 4 payments
  4. GEMTESA $612 55 payments
  5. XTANDI $607 28 payments
  6. Nubeqa $437 19 payments
  7. ELIGARD $413 16 payments
  8. ORGOVYX Hormone Therapy $359 17 payments
  9. Xofigo $321 14 payments
  10. ORGOVYX Oncology $285 18 payments
  11. Other $4,479 200 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,392

Median for Physician Assistant: 241

Drug cost

$385,928

Median for Physician Assistant: $4,110

Branded share of claims

43%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 202 $211,891
Abiraterone Acetate Generic 32 $80,829
Myrbetriq Mirabegron Brand 67 $63,365
Methenamine Hippurate Generic 102 $10,974
Tamsulosin Hcl Generic 238 $4,691
Estradiol Generic 56 $4,030
Cefdinir Generic 127 $1,847
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 16 $1,474
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 92 $1,214
Oxybutynin Chloride Er Oxybutynin Chloride Brand 40 $1,025

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$360,017

Of which drugs: $192,283

Medicare patients

897

Average age 77

Services billed

24,487

398 women, 499 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 40%
Diabetes 38%
Cancer 30%
Chronic kidney disease 27%
Depression 27%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 3,960 $81,932
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 63 496 $69,493
Injection, degarelix, 1 mg J9155 Office 25 8,080 $26,957
Bcg live intravesical instillation, 1 mg J9030 Office 30 4,950 $10,818
Injection, gemcitabine hydrochloride, 200 mg J9201 Office 14 200 $521

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $207
$207 202 —
ERLEADA
  • Janssen Biotech, Inc. $157
$157 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $107
  • PFIZER INC. $22
$130 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $49
$49 — —
Xofigo
  • Bayer HealthCare Pharmaceuticals Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

367 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record